Ignite Creation Date:
2024-07-17 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06463691
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-18
First Post:
2024-06-05
Brief Title:
Sonrotoclax Zanubrutinib and CD20mab in Untreated MCL Patients
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Tianjin Medical University Cancer Institute and Hospital
Study Overview
Official Title:
An Open-label Multi-center Single-arm Study to Evaluate the Efficacy and Safety of Sonrotoclax Zanubrutinib and CD20mab in Untreated MCL Patients
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a an open-label multi-center single-arm study to evaluate the efficacy and safety of sonrotoclax zanubrutinib and CD20mab in untreated MCL patients
Detailed Description:
The benefits of efficacy and survival of immunotherapy regimen in TN MCL is limited and not all patients are fit for receiving chemotherapy Considering the balance of toxicity and efficacy a chemo-free regimen will be a trend in 1L MCL patients The study is to explore the sonrotoclax zanubrutinib and CD20mab combination regimen for TN MCL
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None